Essity AB header image

Essity AB

ESSITY B

Equity

ISIN SE0009922164 / Valor 36851944

NASDAQ Nordic Exchange Stockholm, Equities (2026-04-28)
SEK 245.90+0.37%

Essity AB
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Essity AB is a global hygiene and health company headquartered in Sweden, known for its comprehensive range of products and solutions across various sectors. The company operates in three main business areas: Professional Hygiene, Health & Medical, and Consumer Goods. In Professional Hygiene, Essity provides sustainable hygiene management solutions, including dispensing systems for tissues, soaps, and sanitizers, as well as wiping and cleaning products tailored for commercial and public environments. The Health & Medical segment focuses on supporting patients, caregivers, and healthcare professionals with products and services in incontinence care, wound care, compression therapy, and orthopedics. In the Consumer Goods sector, Essity offers a wide array of personal and home hygiene products, such as baby care, feminine care, incontinence care, and consumer tissue products, catering to various life stages. Essity's commitment to innovation and sustainability is reflected in its diverse product offerings designed to enhance well-being and quality of life.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (26.03.2026):

Essity AB — Quarter 4, 2025 (and full-year 2025): In Q4 2025 Essity reported net sales of SEK 34,695m (down 8.2% y/y), organic sales -1.1%, EBITA SEK 5,005m (+9% y/y) and EBITA excl. IAC SEK 5,117m (+3% y/y) with an EBITA margin excl. IAC of 14.7% (up 1.6 pp). Profit for the period (total operations) was SEK 3,224m (Q4 2024: 2,893) and EPS was SEK 4.69 (4.13). For full-year 2025 net sales were SEK 138,494m (-4.8% y/y), organic sales +0.9%, EBITA SEK 19,503m (flat y/y) and EBITA excl. IAC SEK 19,572m (-4% y/y); profit for the period (total operations) was SEK 12,718m and EPS SEK 18.37. The Board proposes a 6% higher dividend to SEK 8.75 per share and the company continued a SEK 3bn buyback program.

Revenue and growth

Q4 net sales: SEK 34,695m (-8.2% y/y). Organic sales growth Q4: -1.1% (volume -0.2%, price/mix -0.9%). Full-year net sales: SEK 138,494m (-4.8% y/y) with organic growth +0.9% for 2025.

Profitability

Q4 EBITA: SEK 5,005m (+9% y/y). Q4 EBITA excl. IAC: SEK 5,117m (+3% y/y) and EBITA margin excl. IAC 14.7% (up 1.6 percentage points). Full-year EBITA: SEK 19,503m; EBITA excl. IAC SEK 19,572m (-4% y/y) and full-year EBITA margin excl. IAC 14.1% (up 0.1 pp).

Net income and EPS

Q4 profit for the period (total operations): SEK 3,224m (vs 2,893). Q4 EPS: SEK 4.69 (vs 4.13). Full-year profit for the period (total operations): SEK 12,718m (2024: 21,048; note large prior-year discontinued items) and full-year EPS SEK 18.37 (2024: 29.83).

Cash flow and leverage

Q4 operating cash flow: SEK 4,369m (Q4 2024: 3,297). Full-year operating cash flow: SEK 14,998m. Net cash flow, continuing operations in Q4: SEK 2,243m. Net debt at Dec 31, 2025: SEK 26,543m (down SEK 4,226m vs Dec 31, 2024). Net debt/EBITDA excl. IAC: 1.03.

Shareholder returns

Board proposes dividend up 6% to SEK 8.75/share (total ~SEK 5,977m based on outstanding shares at Dec 31, 2025). SEK 3bn buyback program continued in 2025 (total repurchased in 2025: 11,895,826 Class B shares for SEK 3,160m; Q4 repurchase 2,150,228 shares for SEK 555m). Repurchased shares held at year-end: 10,005,826 (≈1.4% of outstanding).

One-off items, costs and programs

Items affecting comparability (IAC) Q4: SEK -131m (mainly restructuring). Essity launched a cost savings program in Q4 targeting ~SEK 1bn annual savings (full effect by end-2026) with estimated restructuring costs ~SEK 1bn (SEK 71m recorded in Q4 2025).

M&A and organizational actions

On Nov 12, 2025 Essity agreed to acquire Edgewell’s feminine care business (brands including Carefree, Stayfree, Playtex); transaction expected to close Q1 2026. New organization effective Jan 1, 2026 and appointments to accelerate growth and supply‑chain enablement were announced.

Other notable metrics

ROCE (Q4) increased to 17.6% (15.8). Gross margin improvements cited (lower input costs and price management). Q4 tax rate ~27.5% (tax expense SEK 1,226m in Q4). Management highlights increased market shares for >65% of branded retail sales and continued sustainability recognitions.

Summarized from source with an LLMView Source

Key figures

-9.70%1Y
-20.9%3Y
-10.3%5Y

Performance

19.2%1Y
18.7%3Y
20.7%5Y

Volatility

Market cap

16521 M

Market cap (USD)

Daily traded volume (Shares)

1,222,711

Daily traded volume (Shares)

1 day high/low

297 / 293.6

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Progyny Inc
Progyny Inc Progyny Inc Valor: 50342281
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 18.38
Ste Virbac SA
Ste Virbac SA Ste Virbac SA Valor: 524407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.88%EUR 366.00
Ramsay Generale de Sante SA
Ramsay Generale de Sante SA Ramsay Generale de Sante SA Valor: 1247709
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.01%EUR 9.84
Robertet SA
Robertet SA Robertet SA Valor: 510354
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%EUR 812.00
Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.79%USD 21.82
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-8.40%USD 24.96
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.52%EUR 26.50
SOLVENTUM CORP
SOLVENTUM CORP SOLVENTUM CORP Valor: 133635906
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.25%USD 67.51
Agenus Inc
Agenus Inc Agenus Inc Valor: 134326284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.89%USD 3.89
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc Edgewise Therapeutics Inc Valor: 110444153
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%USD 30.99